Translation Control Therapeutics
See the light of Protein Translation
New approach
New technology
New drugs

AnimaBiotech

Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation

Translation Control Discovery Platform

Breakthrough Biology

Cloud Architecture

Proprietary Analysis

Translation Control Platform
We purified and fluorescently labeled all 48 types of human tRNA
Using FRET signals from signature tRNA pair(s) of the target protein, we visualize and monitor its translation
Using all 48 tRNA pairs together, we can monitor the cell’s complete protein translation activity
Using the signature pairs for its group of proteins, we can visualize and monitor the translation of a pathway
With multiple proprietary assays, our technology helps in identifying the molecular targets of translation modulating drugs
Multiple secondary assays use proprietary techniques to identify non-toxic compounds that specifically control the target’s translation
State of the art machine learning algorithms analyze billions of data points to identify translation modulating compounds
Proprietary image analysis algorithms run over millions of images to select images where the “translation light” has been affected
85% of known proteins have a “signature tRNA pair” that repeats with high frequency in their sequence but is relatively rare in the background human genome

A new strategy against hard and undruggable targets

Play Video

Specifically decrease or increase the production of target proteins

See the Light of Protein Translation

Translation Control Lab

Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture

Anima Lab

PSM Assays
Screening
VPN

Cloud

Translation Data
Plate Processing
Plate Analysis
Image Analysis
PSM Image Creation
Plate Design
PSM Design
Big Data Visualisation
Bio Data Center
Big Data Analysis
• Experiment Design
• Analysis Assessment
• Bio Data Analysis
The Protein Synthesis Monitoring assay uses labeled tRNA pairs that generate FRET signals to monitor ribosome activity in selected cellular system.
PSM assay in a selected cellular system is used to screen a small molecule library of compounds towards the identification of compounds which change the PSM signal.
Unbiased scores are generated from more than 90 features extracted from images.
Images captured by Operetta® are automatically uploaded to the Cloud using proprietary plate processing software.
QA measures are executed to eliminate outliers wells and cells and to identify false positives.
State of the art image analysis algorithms extract unique PSM and additional cellular features as a feed for the big data analysis.
All images are captured by Operetta®, and the clean, calculated, PSM images is generated automatically.
FRET controls, assay controls are located at specific wells in all screens, enabling strict QA algorithms.
PSM design is based on proprietary mathematical algorithms analyzing the relevant RNA code.
Powerful visual and analytical tools enable us to view the results online from various mathematical and biological angles
All biological data and results are kept in a customized industry standard bio data center.
The analysis utilizes proprietary biological big data algorithms designed for translation control modulators discovery with high level of statistical significance.

Product Pipeline

Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).

Program
Assay Development
Hit Generation
Hit to lead
Preclinical
Collagen I - Target2 Liver Fibrosis
Collagen I - Target3 Scleroderma
RSV Viral Translation Inhibitors
C-Myc Oncology / Longevity
Huntingtin Huntington's disease

Pharma Collaborations

Anima Biotech announces an exclusive collaboration with Lilly for the discovery and development of translation inhibitors of several protein targets

$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.

For partnering inquiries, please contact partnering@animabiotech.com.

17 Scientific Collaborations

14 Publications

Coverage

News & Events

  • 2nd RNA- Targeted Drug Discovery Summit 2019

    When: Dec. 3rd, 2019 - Dec. 4th, 2019
    Where: Boston, USA

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2nd RNA- Targeted Drug Discovery Summit 2019. Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will also participate with other experts as part of the “Targeting RNA with Small Molecules to Capture the Therapeutic Opportunities” panel.

    With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting RNA, the 2nd RNA- Targeted Drug Discovery Summit is the only industry and translational focused conference dedicated to advancing pioneering RNA targeted small molecule therapeutics. For the 2nd year, at this event KOLs and RNA pioneers join to gain a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic, delve into the exciting field of epitranscriptomics and stimulate discussion on how to successfully target RNA via RNA- modifying enzymes and interfering with RNA-protein interactions.

    Download Press Release »

    Visit the conference website »

  • Targeting RNA

    When: Nov. 26th, 2019 - Nov. 27th, 2019
    Where: Frankfurt, Germany

    Anima Biotech has been invited to present a talk on novel targets for small molecules between transcription and translation for lung fibrosis where they will discuss the discovery of lung-specific modulators of collagen translation and give insights into its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the Targeting RNA Europe Congress 2019. Dr. Iris Alroy, Vice President of R&D of Anima Biotech, will also participate in a roundtable discussion on “Discussing RNA Functionality Issues such as Selectivity, Binding, Stability and Specificity” and in the “Treating the Unmet Need: Unleashing the RNA Space With Small Molecules” panel.

    The Targeting RNA Congress explores the ‘undruggable’ RNA space and showcases the latest advancements in modulation of RNA directly with small molecules and through epigenetics. The meeting brings together academic and industry leaders who are building platforms to identify and validate targets in order to assess disease relevance approaches in the RNA world.

    Visit the conference website »

  • BIO-Europe

    When: Nov. 11th, 2019 - Nov. 13th, 2019
    Where: Hamburg, Germany

    Anima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 25th Annual BIO-Europe International Partnering Conference.

    BIO-Europe is Europe’s largest life science partnering conference offering countless opportunities to engage with global life science partners. This event features workshops and panels discussing the latest industry trends in biotech and pharma as well as company presentations and one-on-one partnering meetings.

    Download Press Release »

    Visit the conference website »